Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD

Chart, Trading, Forex, Analysis, Tablet, Pc

Image Source: Pixabay
 

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 15.0%, on average, in February led by Incannex Healthcare that was UP 55.1% as a result of the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse.

Below is how each constituent stock performed in February, in descending order, and YTD, plus any recent news, commentary, and/or analysis on each company:

  1. Incannex Healthcare (IXHL): UP 55.1% in February; UP 17.0% YTD
  2. Mind Medicine (MNMD): UP 48.2% in February; UP 56.3% YTD
  3. GH Research (GHRS): UP 16.6% in February; UP 52.6% YTD
  4. Atai Life Sciences (ATAI): UP 9.0% in February; UP 37.6% YTD
    • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
    • Latest News, Commentary and/or Analysis: None
  5. Compass Pathways (CMPS): DOWN 8.9% in February; UP 17.4% YTD


Summary

The munKNEE Psychedelic compound-Based Drug Stocks Index went UP 15.0% in February and is now UP 32.8% YTD.


More By This Author:

Largest Cannabis LPs Down 6% In February; Now Down 22% YTD
Performance Of 10 Artificial Intelligence Stock Categories Compared Last Week
Bubble In Micro/Small Cap AI Stocks Index Burst Last Week, Down 15%

Disclosure: None

This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with